Impact of uPA system gene polymorphisms on the susceptibility of environmental factors to carcinogenesis and the development of clinicopathology of oral cancer

Annals of Surgical Oncology

Volumn 18, Issue 3, 2011, Pages 805-812

  Weng, Chia Jui ^a   Lin, Chiao Wen ^b   Chung, Tsung Te ^b,c   Tsai, Chiung Man ^d   Chen, Mu Kuan ^b,e   Yang, Shun Fa ^b,f  

^a TAINAN UNIVERSITY OF TECHNOLOGY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^d Chest Hospital   (Taiwan)

^e CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE; UROKINASE RECEPTOR;

ADULT; ALLELE; ARTICLE; BETEL NUT; CANCER RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; FEMALE; GENE; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PLASMINOGEN INACTIVATORS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RISK FACTORS; SURVIVAL RATE; TOBACCO; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 79955747151     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1432-2     Document Type: Article

References (46)

1. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 2003;22:205-22. (Pubitemid 36561058)
2. Duffy MJ, Maguire TM, McDermott EW, O'Higgins N. Urokinase plasminogen activator: A prognostic marker in multiple types of cancer. J Surg Oncol. 1999;71:130-5. (Pubitemid 29288493)
3. Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg. 2002;26:767-71. (Pubitemid 36920315)
4. Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K. Urokinase- type plasminogen activator system and breast cancer (Review). Oncol Rep. 2005;14:105-12.
5. Sakakibara T, Hibi K, Koike M, Fujiwara M, Kodera Y, Ito K, Nakao A. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br J Cancer. 2005;93: 799-803. (Pubitemid 41486440)
6. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 2008;34:122-36.
7. Blasi F, Carmeliet P. uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932-43. (Pubitemid 35477371)
8. Duggan C, Kennedy S, Kramer MD, et al. Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer. 1997;76:622-7. (Pubitemid 27354676)
9. Fredstorp-Lidebring M, Bendahl PO, Brunner N, et al. Urokinase plasminogen activator and its inhibitor PAI-1, in association with progression-free survival in early stage endometrial cancer. Eur J Cancer. 2001;37:2339-48. (Pubitemid 33097469)
10. Janicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst. 2001;93:913-20. (Pubitemid 32624648)
11. Yang SF, Yang WE, Chang HR, Chu SC, Hsieh YS. Luteolin induces apoptosis in oral squamous cancer cells. J Dent Res. 2008;87:401-6.
12. Biolchini F, Pollastri G, Figurelli S, Chiarini L. Carcinogen metabolism, DNA damage repair and oral head and neck squamocellular carcinoma (HNSCC). Minerva Stomatol. 2005;54: 405-14.
13. Nagaraj NS, Beckers S, Mensah JK, Waigel S, Vigneswaran N, Zacharias W. Cigarette smoke condensate induces cytochromes P450 and aldo-keto reductases in oral cancer cells. Toxicol Lett. 2006;165:182-94. (Pubitemid 44202254)
14. Lai KC, Lee TC. Genetic damage in cultured human keratinocytes stressed by long-term exposure to areca nut extracts. Mutat Res. 2006;599:66-75.
15. Yen CY, Liu SY, Chen CH, et al. Combinational polymorphisms of four DNA repair genes XRCC1, XRCC2, XRCC3, and XRCC4 and their association with oral cancer in Taiwan. J Oral Pathol Med. 2008;37:271-7.
16. Vairaktaris E, Yapijakis C, Serefoglou Z, et al. The interleukin- 10 (-1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma. Anticancer Res. 2008;28:309-14. (Pubitemid 351362918)
17. Teng YH, Liu TH, Tseng HC, et al. Contribution of genetic polymorphisms of stromal cell-derived factor-1 and its receptor, CXCR4, to the susceptibility and clinicopathologic development of oral cancer. Head Neck. 2009;31:1282-8.
18. Xu J, Li W, Bao X, et al. Association of putative functional variants in the PLAU gene and the PLAUR gene with myocardial infarction. Clin Sci (Lond). 2010;119:353-9.
19. de Haas EC, Zwart N, Meijer C. Association of PAI-1 gene polymorphism with survival and chemotherapy-related vascular toxicity in testicular cancer. Cancer. 2010 (in press).
20. Chen MK, Tsai HT, Chung TT, et al. Glutathione S-transferase P1 and alpha gene variants; role in susceptibility and tumor size development of oral cancer. Head Neck. 2010;32:1079-87.
21. Ghoshal S, Mallick I, Panda N, Sharma SC. Carcinoma of the buccal mucosa: Analysis of clinical presentation, outcome and prognostic factors. Oral Oncol. 2006;42:533-9.
22. Nanbu R, Menoud PA, Nagamine Y. Multiple instability-regulating sites in the 30 untranslated region of the urokinase-type plasminogen activator mRNA. Mol Cell Biol. 1994;14:4920-8.
23. Lin MH, Wang CJ, Huang HP, Chou MY, Chou FP. The tumorigenic characteristics of lime-piper betel quid-transformed JB6 cells. Arch Toxicol. 2004;78:167-73.
24. Lin PY, Yu CH, Wang JT, Chen HH, Cheng SJ, Kuo MY, Chiang CP. Expression of hypoxia-inducible factor-1 alpha is significantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan. J Oral Pathol Med. 2008;37:18-25. (Pubitemid 350264782)
25. Huang SF, Chen IH, Liao CT, Wang HM, Liou SH, Hsieh LL. Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing. Oral Oncol. 2009;45:16-22.
26. Chang KW, Lee TC, Yeh WI, Chung MY, Liu CJ, Chi LY, Lin SC. Polymorphism in heme oxygenase-1 (HO-1) promoter is related to the risk of oral squamous cell carcinoma occurring on male areca chewers. Br J Cancer. 2004;91:1551-5.
27. Lin SC, Liu CJ, Yeh WI, Lui MT, Chang KW, Chang CS. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett. 2006;243:47-54.
28. Sharma R, Ahuja M, Panda NK, Khullar M. Combined effect of smoking and polymorphisms in tobacco carcinogen-metabolizing enzymes CYP1A1 and GSTM1 on the head and neck cancer risk in North Indians. DNA Cell Biol. 2010;29:441-8.
29. Naina HV, Patnaik MM, Ali UA, Chen D, Ashrani AA. Systemic fibrinolysis caused by tissue plasminogen activator-producing metastatic breast cancer. J Clin Oncol. 2010;28:e167-8.
30. Eriksson P, Kallin B, van't Hooft FM, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogenactivator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995;92:1851-5.
31. Castelló R, Espana F, Vazquez C, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res. 2006;117:487-92. (Pubitemid 43326132)
32. Chen YQ, Sloan-Lancaster J, Berg DT, Richardson MA, Grinnell B, Tseng-Crank J. Differential mechanisms of plasminogen activator inhibitor-1 gene activation by transforming growth factor-beta and tumor necrosis factor-alpha in endothelial cells. Thromb Haemost. 2001;86:1563-72. (Pubitemid 34007533)
33. Swiatkowska M, Szemraj J, Cierniewski CS. Induction of PAI-1 expression by tumor necrosis factor alpha in endothelial cells is mediated by its responsive element located in the 4G/5G site. FEBS J. 2005;272:5821-31. (Pubitemid 41689354)
34. Janicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase- type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost. 1991;17:303-12.
35. Nielsen HJ, Pappot H, Christensen IJ, et al. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. Br Med J. 1998;316: 829-30. (Pubitemid 28112429)
36. Smolarz B, Blasiak J, Kulig A, et al. Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer. J Exp Clin Cancer Res. 2001; 20:247-52. (Pubitemid 32641068)
37. Loktionov A, Watson MA, Stebbings WS, Speakman CT, Bingham SA. Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis. Cancer Lett. 2003;189:189-96. (Pubitemid 35461995)
38. Alvarez-Millán JJ, Bocos C, Ferrín V, Lucas AR, Ruibal A, Schneider J. PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells. Oncology. 2002;62:286-90. (Pubitemid 34639063)
39. Manders P, Tjan-Heijnen VC, Span PN, et al. Complex of urokinase- type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Cancer. 2004;101:486-94. (Pubitemid 38970599)
40. Sciacca FL, Ciusani E, Silvani A, et al. Genetic and plasma markers of venous thromboembolism in patients with high-grade glioma. Clin Cancer Res. 2004;10:1312-7. (Pubitemid 38365222)
41. Yasuda T, Sakata Y, Kitamura K, Morita M, Ishida T. Localization of plasminogen activators and their inhibitor in squamous cell carcinoma of the head and neck. Head Neck. 1997;19:611-6. (Pubitemid 27407316)
42. Curino A, Patel V, Nielsen BS, et al. Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. Oral Oncol. 2000;40:1026-32. (Pubitemid 39422788)
43. Hundsdorfer B, Zeilhofer HF, Bock KP, et al. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal neoplastic tissues of patients with squamous cell cancer of the oral cavity: Clinical relevance and prognostic value. Craniomaxillofac Surg. 2005;33:191-6. (Pubitemid 40614180)
44. Bajou K, Maillard C, Jost M, et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene. 2004;23:6986-90. (Pubitemid 39279999)
45. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase- type plasminogen activator system in cancer metastasis: A review. Int J Cancer. 1997;72:1-22. (Pubitemid 27314632)
46. Czekay RP, Loskutoff DJ. Unexpected role of plasminogen activator 1 in cell adhesion and detachment. Exp Biol Med. 2004;229:1090-6. (Pubitemid 39602250)